OOIR: Observatory of International Research

Papers

(The TQCC of Neurology-Neuroimmunology & Neuroinflammation is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Differential Binding of Autoantibodies to MOG Isoforms in Inflammatory Demyelinating Diseases	150
A 28-Year-Old Woman With Left-Sided Weakness and Atypical MRI Lesions	149
Immunohistologic Features of Cerebral Venous Thrombosis Due to Vaccine-Induced Immune Thrombotic Thrombocytopenia	130
Natalizumab Treatment Induces Proinflammatory CD4 T Cells Preferentially in the Integrin β7+ Compartment	120
Comment: Humoral and T-cell Immunities to SARS-CoV-2 Vaccines: Safety, Efficacy, and Challenges in Autoimmune Neurology	117
Early-Stage Contactin-Associated Protein-like 2 Limbic Encephalitis	105
Relapsing and Immune-Responsive Paroxysmal Jaw Clonus With Blepharospasm and Sialorrhea Associated With D2R Autoantibodies	100
Antibody-Negative Autoimmune Encephalitis	85
CSF Concentrations of CXCL13 and sCD27 Before and After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis	85
T-Cell Specificity Influences Disease Heterogeneity in Multiple Sclerosis	82
Cortical and Subcortical Dysmetabolism Are Dynamic Markers of Clinical Disability and Course in Anti-LGI1 Encephalitis	72
Longitudinal T-Cell Responses After a Third SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis on Ocrelizumab or Fingolimod	72
Clinical Presentation, Management, and Diagnostic Performance of 2021 Criteria for Paraneoplastic Neurologic Syndromes in Childhood	70
Pro-Inflammatory Molecules Implicated in Multiple Sclerosis Divert the Development of Human Oligodendrocyte Lineage Cells	68
Early Immunotherapy and Longer Corticosteroid Treatment Are Associated With Lower Risk of Relapsing Disease Course in Pediatric MOGAD	67
Relapsing-Remitting Immunotherapy Responsive Small-Fiber Neuropathy	66
Synaptic Protein Loss in Extracellular Vesicles Reflects Brain and Retinal Atrophy in People With Multiple Sclerosis	61
Intrathecal Inflammatory Profile and Gray Matter Damage Predict Progression Independent of Relapse Activity in Early Multiple Sclerosis	61
Should We Measure CSF Complement Levels in Patients With MOGAD?	61
COVID-19 in Patients With Neuromyelitis Optica Spectrum Disorders and Myelin Oligodendrocyte Glycoprotein Antibody Disease in North America	60
Cell-Free DNA Derived From Neutrophils Triggers Type 1 Interferon Signature in Neuromyelitis Optica Spectrum Disorder	59
TNF-Blockade for Primary Stroke Prevention in Adenosine Deaminase 2 Deficiency	55
CXCL10/IgG1 Axis in Multiple Sclerosis as a Potential Predictive Biomarker of Disease Activity	49
Acute Paresthesia and Ataxia in a Child	48
Peripheral Immune Profiles Predict ALS Progression in an Age- and Sex-Dependent Manner	48

Encephalitis and Myelitis in a Young Woman	47
Treatment With Erythropoietin for Patients With Optic Neuritis	46
Patients With Severe Multiple Sclerosis Exhibit Functionally Altered CD8 ⁺ Regulatory T Cells	46
Baicalin Promotes CNS Remyelination via PPARγ Signal Pathway	46
Genome-wide Association Study Identifies 2 New Loci Associated With Anti-NMDAR Encephalitis	45
Plasma Biomarkers of Neuropathogenesis in Hospitalized Patients With COVID-19 and Those With Postacute Sequelae of SARS-CoV-2 Infection	44
Toward Precision Phenotyping of Multiple Sclerosis	44
Timing of MOG-IgG Testing Is Key to 2023 MOGAD Diagnostic Criteria	44
Immunotherapy-Responsive Neuropathic Pain and Allodynia in a Patient With Glycine Receptor Autoantibodies	43
Increased Intracranial Pressure in Pediatric Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease	43
Retinal Optical Coherence Tomography in Neuromyelitis Optica	43
Novel Cell-Based Assay for Alpha-3 Nicotinic Receptor Antibodies Detects Antibodies Exclusively in Autoimmune Autonomic Ganglionopathy	43
Comparative Study of Paraneoplastic and Nonparaneoplastic Autoimmune Encephalitis With GABA _B R Antibodies	43
Trigeminal Nerve Involvement in Bulbar-Onset Anti-IgLON5 Disease	42
Proteomics Analysis Moves the Needle by Generating Clinical Diagnostic Markers	42
Epstein-Barr Virus in the Cerebrospinal Fluid and Blood Compartments of Patients With Multiple Sclerosis and Controls	42
Antineonatal Fc Receptor Antibody Treatment Ameliorates MOG-IgG–Associated Experimental Autoimmune Encephalomyelitis	41
Clinical Manifestations and Treatment Responses in Pediatric Neurofascin 155-IgG4 Autoimmune Nodopathy	41
Clinical Features of Children With MOG-IgG Who Fulfill Criteria of Multiple Sclerosis and Overlapping Disorders	41
The Role of Complement Activation in IgM M-Protein–Associated Neuropathies	41
Blocking Placental Class G Immunoglobulin Transfer Prevents NMDA Receptor Antibody Effects in Newborn Mice	41
Sustained Low Relapse Rate With Highly Variable B-Cell Repopulation Dynamics With Extended Rituximab Dosing Intervals in Multiple Sclerosis	40
B-Cell Compartmental Features and Molecular Basis for Therapy in Autoimmune Disease	40
Antiplexin D1 Antibodies Relate to Small Fiber Neuropathy and Induce Neuropathic Pain in Animals	40
Effect of Prior Treatment With Fingolimod on Early and Late Response to Rituximab/Ocrelizumab in Patients With Multiple Sclerosis	40
Neuropsychological Testing in Autoimmune Encephalitis: A Scoping Review	40
A 42-Year-Old Woman With Rapidly Expanding White Matter Lesions	39
Clinicopathologic Profiles of Sporadic Late-Onset Nemaline Myopathy	38
Absence of Systemic Oxidative Stress and Increased CSF Prostaglandin F2α in Progressive MS	37
miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis	36
Paraneoplastic Cerebellar Degeneration With P/Q-VGCC vs Yo Autoantibodies	35
Peptides From the Variable Domain of Immunoglobulin G as Biomarkers in Chronic Inflammatory Demyelinating Polyradiculoneuropathy	35
Acknowledgment to Reviewers	35
Interim Analysis of Pregnancy Outcomes After Exposure to Dimethyl Fumarate in a Prospective International Registry	34
Pediatric MOG-Ab–Associated Encephalitis	33
Cognitive Impairment, Associated Clinical Factors, and MR Volumetric Measures in Myelin Oligodendrocyte Glycoprotein-IgG–Associated Disease	33
“Will the Real Demyelinating Disorder Please Stand Up?”	32
Deep Phenotyping of Neurologic Postacute Sequelae of SARS-CoV-2 Infection	32
Racial and Ethnic Disparities in the Incidence of Anti-NMDA Receptor Encephalitis	31
Clinical and Immunologic Effects of Paraprobiotics in Long-COVID Patients	31
Modeling MOG Antibody–Associated Disorder and Neuromyelitis Optica Spectrum Disorder in Animal Models	31
Chronic Dengue Virus Encephalitis	31
B Cells in the CNS at Postmortem Are Associated With Worse Outcome and Cell Types in Multiple Sclerosis	31
Elsberg Syndrome Secondary to Cytomegalovirus Infection in an Immunocompetent Patient	30
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies	30
Recovery From COVID-19 in Multiple Sclerosis	30
Neurologic Manifestations of Common Variable Immunodeficiency	30
Cortical Thickness and Serum NfL Explain Cognitive Dysfunction in Newly Diagnosed Patients With Multiple Sclerosis	30
Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19	29
Alterations in Gut Microbiome-Host Relationships After Immune Perturbation in Patients With Multiple Sclerosis	29

Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab	29
Cryptococcal Meningitis Reported With Fingolimod Treatment	29
CCR5 Blockade in Inflammatory PML and PML-IRIS Associated With Chronic Inflammatory Diseases' Treatments	29
Distinguishing Transient From Persistent Brain Structural Changes in Pediatric Patients With Acute Disseminated Encephalomyelitis	29
Rituximab Use for Relapse Prevention in Anti-NMDAR Antibody-Mediated Encephalitis	29
Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis	29
Ten Years of Neurology ® Neuroimmunology & Neuroinflammation	29
Clinical Characterization and Ancillary Tests in Susac Syndrome	29
Early Neuroaxonal Damage in Neurologic Disorders Associated With GAD65 Antibodies	29
mRNA COVID-19 Vaccination Does Not Exacerbate Symptoms or Trigger Neural Antibody Responses in Multiple Sclerosis	28
Chronic Active Lesions and Larger Choroid Plexus Explain Cognition and Fatigue in Multiple Sclerosis	28
MRI Features and Their Association With Outcomes in Children With Anti-NMDA Receptor Encephalitis	28
PET Study of Microglial Activation in Kleine-Levin Syndrome	28
Immune Profiling Reveals the T-Cell Effect of Ocrelizumab in Early Relapsing-Remitting Multiple Sclerosis	27
Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival	27
Assessing Commercial Tissue-Based Assays for Autoimmune Neurologic Disorders (I)	27
Retinal Damage and Visual Network Reconfiguration Defines Visual Function Recovery in Optic Neuritis	27
Progressive Encephalomyelopathy in an Older Man	26
HLA-DRB115:01 and the MERTK* Gene Interact to Selectively Influence the Profile of MERTK-Expressing Monocytes in Both Health and MS	26
Disease-Modifying Treatments for Multiple Sclerosis Affect Measures of Cellular Immune Responses to EBNA-1 Peptides	26
Rate of Retinal Layer Thinning as a Biomarker for Conversion to Progressive Disease in Multiple Sclerosis	26
Anti-Hu Antibodies in Patients With Neurologic Side Effects of Immune Checkpoint Inhibitors	26
Early Neuroaxonal Damage in Neurologic Disorders Associated With GAD65 Antibodies	25
Pediatric MOG-Ab–Associated Encephalitis	25
Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis	25
Area Postrema Syndrome in Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy	24
Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis	24
Neuropsychological Testing in Autoimmune Encephalitis	24
Ravulizumab and Efgartigimod in Myasthenia Gravis	23
Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis	23
Extracellular Vesicle Marker Changes Associated With Disease Activity in Relapsing-Remitting Multiple Sclerosis	23
Multiple Sclerosis Disease Activity and Disability Following Cessation of Fingolimod for Pregnancy	22
CNS Antigen-Specific Neuroinflammation Attenuates Ischemic Stroke With Involvement of Polarized Myeloid Cells	22
CAR-T Cell–Mediated B-Cell Depletion in Central Nervous System Autoimmunity	22
SARS-CoV-2–Specific Immune Responses in Patients With Postviral Syndrome After Suspected COVID-19	22
Cerebellar Ataxia With Anti-DNER Antibodies	22
Presentation and Outcome in S1P-RM and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy	22
Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort	22
Antibody Investigations in 2,750 Children With Suspected Autoimmune Encephalitis	21
Different Complement Activation Patterns Following C5 Cleavage in MOGAD and AQP4-IgG+NMOSD	21
Association of NEDA-4 With No Long-term Disability Progression in Multiple Sclerosis and Comparison With NEDA-3	21
Inflammatory Activity After Diverse Fertility Treatments	21
Imaging Characteristics of Choroid Plexuses in Presymptomatic Multiple Sclerosis	21
Mutational Profile in 75 Patients With Anti–Myelin-Associated Glycoprotein Neuropathy	21
Progressive Myelitis in a 63-Year-Old Woman	21
Mitoxantrone in NMO Spectrum Disorder in a Large Multicenter Cohort in French Caribbean	21
Familial History of Autoimmune Disorders Among Patients With Pediatric Multiple Sclerosis	20
Microstructural Damage and Repair in the Spinal Cord of Patients With Early Multiple Sclerosis and Association With Disability at 5 Years	20
A 79-Year-Old Woman With Worsening Headaches and Pachymeningeal Enhancement	20
Single-Cell Multi-Omics Map of Cell Type–Specific Mechanistic Drivers of Multiple Sclerosis Lesions	20
Serological Markers of Clinical Improvement in MuSK Myasthenia Gravis	20
Siponimod Inhibits the Formation of Meningeal Ectopic Lymphoid Tissue in Experimental Autoimmune Encephalomyelitis	20
Retinal Changes in Double-Antibody Seronegative Neuromyelitis Optica Spectrum Disorders	20
Neuromyelitis Optica Spectrum Disorders in Africa	20
Immune Checkpoint Inhibition–Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade	20
Temporal Lobe Epilepsy Associated With Glutamic Acid Decarboxylase Antibodies	20
Increased NLRP3 Inflammasome Activation and Pyroptosis in Patients With Multiple Sclerosis With Fingolimod Treatment Failure	20
Dynamics of Retinal Vessel Loss After Acute Optic Neuritis in Patients With Relapsing Multiple Sclerosis	20
Neurofilament Light in CSF and Plasma Is a Marker of Neuronal Damage in HTLV-1–Associated Myelopathy and Correlates With Neuroinflammation	20
Identification of Distinct Biological Groups of Patients With Cryptogenic NORSE via Inflammatory Profiling	20
Multiple Sclerosis Patient Macrophages Impaired Metabolism Leads to an Altered Response to Activation Stimuli	19
Seizure Semiology in Antibody-Associated Autoimmune Encephalitis	19
Dramatic Response to Anti-IL-6 Receptor Therapy in Children With Life-Threatening Myelin Oligodendrocyte Glycoprotein-Associated Disease	19
Dimethyl Fumarate Reduces Inflammation in Chronic Active Multiple Sclerosis Lesions	19
COVID-19 Vaccination Reactogenicity in Persons With Multiple Sclerosis	19
COVID-19 Severity in Multiple Sclerosis	19
Combined Treatment With Pembrolizumab and Allogenic BK Virus-Specific T Cells in Progressive Multifocal Leukoencephalopathy	19
Neurofilament Light Chain as a Discriminator of Disease Activity Status in MOG Antibody-Associated Disease	19
Autopsy Case of Meningoencephalomyelitis Associated With Glial Fibrillary Acidic Protein Antibody	19
Comparison of Structural Changes in Nodding Syndrome and Other Epilepsies Associated With Onchocerca volvulus	19